Mydriacyl (Tropicamide)

Tropicamide blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. This inhibition prevents parasympathetic‑mediated constriction of the pupil and accommodation, leading to rapid pupil dilation (mydriasis) and loss of focusing power (cycloplegia) that facilitate ocular assessment and surgery.

The prescribed dose of Mydriacyl is determined by the treating eye‑care professional. Typically, one or two drops are instilled in the conjunctival sac of the target eye(s) as directed, with the interval and frequency set according to the specific clinical need.

Safety data for tropicamide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use only if the potential benefit justifies any possible risk to the fetus or infant, and discuss with a healthcare provider before treatment.

To request Mydriacyl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mydriacyl (tropicamide) provides a relatively rapid onset and short duration of action compared with longer‑acting agents such as phenylephrine or cyclopentolate. This makes it suitable for routine examinations where brief dilation is desired, while other agents may be preferred for prolonged surgical procedures.

Mydriacyl should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from direct light and moisture to maintain stability and potency throughout its shelf life.

Mydriacyl is applied topically to the eye as an ophthalmic solution. The recommended method is to instill the prescribed number of drops into the conjunctival sac of each eye, avoiding contact with the eyelid or lashes, and to observe the patient for the desired dilation effect.

The most serious adverse events include acute angle‑closure glaucoma, severe allergic reactions (e.g., eyelid swelling, rash), and rare systemic anticholinergic toxicity. Patients should be monitored for signs of increased intraocular pressure or hypersensitivity, and treatment should be discontinued if serious reactions occur.

Mydriacyl is contraindicated in individuals with known hypersensitivity to tropicamide or any formulation component, and it should be avoided in patients with narrow‑angle or acute angle‑closure glaucoma unless specifically directed by an ophthalmologist.